| Literature DB >> 26148990 |
Raphael Rapetti-Mauss1, Caroline Lacoste2, Véronique Picard3, Corinne Guitton4, Elise Lombard5, Marie Loosveld6, Vanessa Nivaggioni6, Nathalie Dasilva7, David Salgado7, Jean-Pierre Desvignes7, Christophe Béroud2, Patrick Viout8, Monique Bernard8, Olivier Soriani1, Henri Vinti9, Valérie Lacroze10, Madeleine Feneant-Thibault11, Isabelle Thuret12, Hélène Guizouarn1, Catherine Badens13.
Abstract
The Gardos channel is a Ca(2+)-sensitive, intermediate conductance, potassium selective channel expressed in several tissues including erythrocytes and pancreas. In normal erythrocytes, it is involved in cell volume modification. Here, we report the identification of a dominantly inherited mutation in the Gardos channel in 2 unrelated families and its association with chronic hemolysis and dehydrated cells, also referred to as hereditary xerocytosis (HX). The affected individuals present chronic anemia that varies in severity. Their red cells exhibit a panel of various shape abnormalities such as elliptocytes, hemighosts, schizocytes, and very rare stomatocytic cells. The missense mutation concerns a highly conserved residue among species, located in the region interacting with Calmodulin and responsible for the channel opening and the K(+) efflux. Using 2-microelectrode experiments on Xenopus oocytes and patch-clamp electrophysiology on HEK293 cells, we demonstrated that the mutated channel exhibits a higher activity and a higher Ca(2+) sensitivity compared with the wild-type (WT) channel. The mutated channel remains sensitive to inhibition suggesting that treatment of this type of HX by a specific inhibitor of the Gardos channel could be considered. The identification of a KCNN4 mutation associated with chronic hemolysis constitutes the first report of a human disease caused by a defect of the Gardos channel.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26148990 DOI: 10.1182/blood-2015-04-642496
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113